Ian B. Li
Adele C. Oliva
Adele Oliva has been a healthcare investor for over 20 years and founded 1315 Capital in 2014 to establish an investment firm focused on healthcare growth equity and buyouts. The firm has since raised multiple funds and has over $1 billion under management. Adele was recruited to Quaker Partners in 2007 to expand their growth stage investing practice. Prior to Quaker, she was Co-Head of US Healthcare at Apax Partners, where she spent a decade in both Silicon Valley and Manhattan.
Prior to entering private equity as a Kauffman Fellow, Adele held roles at CoreStates and Baxter Healthcare. Adele received a BSc from St. Joseph’s University and an MBA from Cornell University, where she was awarded the Albert Fried Fellowship.
Adele has served on the board of Ascent Healthcare Solutions (acquired by Stryker), EKR Therapeutics (acquired by Cornerstone Therapeutics), ESP Pharma (acquired by Protein Design Labs), Esprit Pharma (acquired by Allergan), Genoptix (acquired by NeoGenomics), Precision Dermatology (acquired by Valeant), Prometheus Labs (acquired by Nestle), and SkinMedica (acquired by Allergan). She currently serves on the boards of 3B Scientific, Colorescience, Homestead Smart Health Plans, Innovative Health, miraDry, and Onkos Surgical.
Michael Koby co-founded 1315 Capital in 2014, after spending his entire career as a healthcare investor and operator, including experience with more than 25 growth equity investments. Prior to founding 1315 Capital, Michael was a Managing Director at Palm Ventures, a private-equity focused family office where he led all healthcare investing. While at Palm, Michael led investments in Enigma Diagnostics, Axcentria Pharmaceuticals, and JDS Therapeutics. He currently serves on the boards of CHC Solutions, CortiCare, Innovative ECMO Concepts, and JDS Therapeutics.
Before Palm Ventures, Michael spent over a decade as an investor, including before and after business school, at Galen Partners, a healthcare growth equity investment firm. He also held business development roles at Novoste Corporation and Medtronic, Inc. Michael started his career as a healthcare investment banking analyst at Dillon, Read & Co.
Michael received a BSc from Cornell University and an MBA in Healthcare Management from The Wharton School.
Matthew joined 1315 Capital as Partner in 2017, bringing extensive healthcare investing experience across debt and equity transactions. Prior to joining 1315 Capital, he spent 9 years at HealthCare Royalty Partners, most recently as a Managing Director. He currently serves on the board of ProSciento and Restorative Therapies, and previously served on the board of Reaction Biology (acquired by Cobepa) and Verogen (acquired by QIAGEN). Matthew also serves on the Board of Directors of Life Sciences Pennsylvania.
Matthew has over two decades of growth stage investing experience with a focus on the specialty pharmaceutical, pharmaceutical outsourcing, and medical technology sectors. Prior to HealthCare Royalty Partners, Matthew worked at Accretive LLC and Paul Capital Partners. Earlier in his career, he worked as a principal investor focused on the healthcare industry at Oak Hill Capital Partners and J.H. Whitney & Co. Matthew started his career as a healthcare investment banker at Morgan Stanley. Matthew has worked on over $1 billion in healthcare financings over the course of his career.
Matthew received a BSc in Engineering, magna cum laude, from Princeton University, an MBA with honors from The Wharton School of the University of Pennsylvania, and a Master of Biotechnology degree from the University of Pennsylvania.
Edward Chan joined 1315 Capital in 2016 after spending 5 years at NaviMed Capital. Prior to joining NaviMed Capital, Edward was part of the healthcare investment team at Siemens Venture Capital. Edward also held an investment role at SAC Capital and a marketing role at Medtronic Cardiovascular. Edward started his career developing and commercializing a molecular diagnostic product at a venture backed company.
Edward has served on the board or as a board observer at the following companies: Genoptix (acquired by NeoGenomics), Centurion Service Group (acquired by TRIMEDX), CenterPointe Behavioral Health System (acquired by Acadia Healthcare), and Greenbrook TMS. He currently serves on the board of Homestead Smart Health Plans, Innovative ECMO Concepts, and Interpace Biosciences.
Edward received a BSc in Biomedical Engineering from Johns Hopkins University and an MBA in Healthcare Management and Finance from the Wharton School at the University of Pennsylvania.
Ian B. Li
Ian Li joined 1315 Capital in 2015 and is a Principal on the investment team. Prior to investing, Ian was a healthcare management and strategy consultant at Capgemini Consulting and had experience working at Stryker Orthopaedics in the quality engineering department.
Ian currently serves on the board of 3B Scientific, CortiCare, and miraDry, and is a board observer for Colorescience and Nutrisense. Ian also serves as Co-Chair of the Duke University Philadelphia Alumni Board, is on the board of Philadelphia’s Magic Gardens, and is on the leadership team of Out Investors.
Ian received a BSE in Biomedical Engineering from Duke University, with a minor in Economics.
Craig Matturro joined 1315 Capital in 2016 after two years as an Analyst in the Investment Banking Group of Leerink Partners, LLC, where he worked on multiple M&A and private placement engagements for small to mid-cap public and private companies across all healthcare subsectors.
During his time at 1315 Capital, Craig went on secondment to serve as Director of Business Development for 1315 Capital portfolio company, JDS Therapeutics, where he led the divesture of the Company’s Nutrition21 division to Everwell Health, as well as the acquisition of patented nutraceutical assets by the Company’s Bonafide Health division (acquired by Pharmavite).
Craig currently serves on the board of Restorative Therapies and Triple Ring Technologies, is a board observer for Onkos Surgical, and previously was a board observer for Solsys Medical (acquired by Misonix) and Centurion Service Group (acquired by TRIMEDX).
Craig received a BSc from Carnegie Mellon University in Business Administration – Concentration in Finance with University Honors, and a minor in Engineering Studies.
Jordan Brown joined 1315 Capital in 2020. Previously, Jordan worked on the investment team at Northwell Ventures, where she managed investments in several early-stage HIT, medical technology and healthcare services businesses. In this role, she was actively involved in sourcing, due diligence and investment, as well as support of portfolio companies. Jordan also has experience in biotechnology M&A. She began her career at Piper Sandler (fka Piper Jaffray) in their Healthcare Investment Banking group.
Ryan Kraus joined 1315 Capital in 2020. Previously, he worked as an Analyst at MTS Health Partners, focusing on M&A and financing transactions across the pharmaceutical, biotechnology, and healthcare services subsectors. Prior to MTS, Ryan worked at Pacira BioSciences in Corporate Strategy and Business Development.
Ryan received a BS in Finance, summa cum laude, from Rutgers University.
Director of Business Development
Jamie Richardson joined 1315 Capital in 2020, after spending over three years at ProMedica, most recently as an Investment Associate. In this role, Jamie worked on numerous debt and equity financings of innovative healthcare companies and led the due diligence, investment committee approval and transaction process for companies in the ProMedica Ventures portfolio. He also supported portfolio companies and worked with entrepreneurs to help their companies with business and financial strategy throughout the life of the investment.
Jamie received a BA and MBA in Finance from the University of Toledo where he represented the Varsity Golf Team as an NCAA Division 1 Student Athlete.
Carter Cortazzi joined 1315 Capital in 2022 after spending 3 years at Archetype Growth, most recently as an Investment Associate. In this role, he was actively involved in the sourcing, selection, structuring, and execution of multiple investments across the healthcare services, digital health, and insurance technology sectors. He also supported portfolio companies with corporate development, fundraising, and operations. Prior to Archetype, Carter co-founded a company in the ocean conservation technology space.
Carter received a BA in Philosophy from Georgetown University.
Business Development Associate
Rohini Mandal joined 1315 Capital in 2024 after spending 2 years at Alvarez & Marsal’s Life Sciences Business Unit as a management consulting analyst. In this role, she was engaged by multiple biopharma and hospital clients seeking to improve their operational performance.
Rohini received a BA in Quantitative Social Science from Dartmouth College, with a minor in Global Health.
Chief Financial Officer & Chief Compliance Officer
Brian Schwenk joined 1315 Capital in 2014, and has 14 years of experience in private equity and public accounting. Since 2012, Brian has worked with Adele Oliva at Quaker Partners as Chief Financial Officer. His roles at 1315 Capital include oversight of accounting, treasury, financial reporting, and performance analysis as well as human resources, investor relations, information technology, risk management, and compliance.
Brian also spent nearly 7 years at an affiliate of Quaker, Independence Capital Partners, most recently as Senior Controller. Earlier in his career, Brian worked for American Express Tax & Business Services, Stout Causey Consulting, and Arthur F. Bell, Jr. & Associates as an audit associate.
Brian received a BA in management with a concentration in Accounting from Gettysburg College and an MBA with a concentration in Accounting from Loyola College in Maryland.
Jacqueline Akpan, CPA joined 1315 Capital in 2018 and has three years of experience in public accounting. Prior to joining 1315 Capital, Jacqueline worked at KPMG LLP as an auditor, where she audited companies within the financial services industry. Her roles at 1315 Capital include assisting the CFO with accounting, reporting and administration of investment vehicles.
Jacqueline received a BBA from Temple University, with a major in Accounting and a minor in Finance.
Steven St. Peter, M.D.
Operating Team Member
Scott Cramer is an Operating Team Member at 1315 Capital, a healthcare expansion and growth equity firm. Scott has over 35 years’ experience and is a proven and focused medical device, diagnostics and consumer products CEO. He has significant experience driving change by instilling a culture of high performance and implementing growth strategies as well as operational improvement initiatives, resulting in a track-record of successful exits.
Most recently Scott was CEO of DNA Diagnostics Center which was a world leader in paternity and relationship testing. The company was acquired by Eurofins in August 2021.
Prior to DDC, Scott served as the President & CEO of Accriva Diagnostics. The Company had a portfolio of diagnostics devices for coagulation and platelet function testing. The Company closed all NJ operations and moved to a new facility in San Diego. Accriva was successfully sold to Werfen Life in January 2017.
Previously Scott was President and CEO of Novasys Medical. The Company was focused on treating women with stress incontinence. Novasys was sold to Roper Industries in Dec. 2012. Prior to joining Novasys, he served as President and CEO of Bacchus Vascular, a company focused on peripheral vascular disease, where he successfully negotiated the sale of the Company to Covidien plc in March 2009.
Prior to his CEO roles Scott was the Senior Vice President of U.S. Sales and Services for VNUS Medical, which was also acquired by Covidien plc. Scott joined VNUS in 2000. From 1997 through 2000, Scott was Vice President Sales at EndoSonics, a cardiovascular device company which later became Volcano Corporation. From 1996 to 1997, he served as NSM at Cardiometrics, which was acquired by Endosonics Corporation. From 1990 to 1995, Scott held several positions at Baxter Healthcare Corporation’s cardiovascular division.
Scott currently serves on the board of Biocoat, CortiCare, and Harmac Medical Products. Scott served as Executive Chairman of NeuWave Medical (acquired by J&J), and has also previously served on the BOD of DDC, Accriva, Veran Medical (acquired by Olympus), Vascular Insights (acquired by Merit Medical), AccuVein, Novasys and Bacchus. He holds a B.S. degree in Finance from Philadelphia University.
Operating Team Member
Tom Burnell is an Operating Team Member at 1315 Capital, a healthcare expansion and growth equity firm. Tom has a wealth of experience across healthcare including diagnostics, pharmaceutical services, laboratory services, dietary supplements, and contract manufacturing industries, with an outstanding track record of leading organizational change and orchestrating turnarounds, accelerating growth for startups, and facilitating post-acquisition integration. He has international business development experience spanning 38 countries on 5 continents, achieved triple-digit EBITDA growth in several businesses, and facilitated 39 M&A transactions, creating over $1 billion in shareholder value. Tom was a former Operating Partner at Ampersand Capital Partners, where he served as CEO and/or Executive Chairman of two Ampersand portfolio companies, and he is currently President and CEO of Interpace Biosciences, Inc., a 1315 Capital II, L.P. portfolio company. Tom has a B.S in Animal Science and an M.S. in Animal Nutrition from the University of Nebraska, and a Ph.D. in Nutrition, with an emphasis in Statistics and Biochemistry, from the University of Kentucky.
Operating Team Member
Tim Einwechter is an Operating Team Member at 1315 Capital, a healthcare expansion and growth equity firm. Tim is co-founder and Chief Financial Officer of Innovative Health, a medical device reprocessing company focused on cost containment, particularly in the cardiology space. Prior to Innovative Health, he was co-founder and Chief Financial Officer for Intralign. Tim was also Chief Financial Officer of Alliance Medical, and later Ascent Healthcare Solutions (acquired by Stryker for $525 million). Prior to joining Alliance Medical, Tim was Chief Operating Officer of Healthworks Managed Care Services, a private company engaged in the provision of rehabilitation services. He also spent time as Chief Financial Officer of Dynacare Health Services, a publicly traded health services company engaged in the business of providing home healthcare and laboratory diagnostic services, and before that tenured as a Vice President of Versa-Care, a company engaged in the provision of accommodation for senior citizens. Tim also serves on the Board of Directors for CHC Solutions.
Tim was named Arizona’s 2010 Private Company CFO of the Year by the Financial Executives Institute.
Tim received an Honors BA in Business Administration from Wilfrid Laurier University and is a Chartered Accountant.
Operating Team Member
Rick Ferreira is an Operating Team Member at 1315 Capital, a healthcare expansion and growth equity firm. Rick is a serial entrepreneur and currently President & CEO of Innovative Health, a medical device reprocessing company he co-founded focused on cost containment, particularly in the cardiology space. Prior to Innovative Health, Rick was President & CEO of Intralign, a company he co-founded to help hospitals and surgeons reduce costs and improve efficiencies around joint replacement surgery. Prior to Intralign, Rick founded Alliance Medical in 1997, the first major medical device reprocessing company. Alliance Medical merged with Vanguard Medical Concepts in 2005 to become Ascent Healthcare Solutions (acquired by Stryker for $525 million). Rick previously served on the Board of Directors of Centurion Service Group (acquired by Trimedx, LLC in 2020).
Rick started his first company, International Managed Healthcare, a Canadian company engaged in the provision of rehabilitation services, in 1990. The company was sold to Liberty Mutual Insurance in 1994. Rick began his career with the Royal Bank of Canada.
Rick received a BA in Business Administration from the University of Toronto.
Operating Team Member
Antony Koblish is an Operating Team Member at 1315 Capital, a healthcare expansion and growth equity firm. Antony is a medical device entrepreneur with 25 years of experience in healthcare. Antony is co-founder and President & CEO of TELA Bio, a biosurgical reconstruction company based in Malvern, Pennsylvania. Prior to founding TELA Bio, Antony was President and CEO of Orthovita, Inc., a publicly traded orthobiologics and biosurgery medical device company. During his tenure as CEO of Orthovita from 2002 to 2011, Antony created significant company value, growing valuation from $30 million to a $316 million sale to Stryker Corporation in May 2011. Antony is a skilled leader with a proven track record in driving sales growth, building a robust product pipeline, establishing world-class commercial operations, and instilling clinical & manufacturing quality.
Antony is also a co-founder and currently serves as Chairman of the Board of Onkos Surgical, a surgical oncology company, and on the Board of Directors for miraDry.
Antony received a BSc in Mechanical Engineering from Worcester Polytechnic Institute, and an MS in Mechanical Engineering & Applied Mechanics from the University of Pennsylvania.
Operating Team Member
Robert Schrepfer’s career in healthcare and investing has spanned over 25 years, including sell-side research coverage of the pharmaceutical industry at Bear Stearns, portfolio management at Healthcare Value Capital where he managed the firm’s private equity portfolio as well as investments in services, devices and specialty pharmaceuticals and most recently as SVP of Generics at McKesson. He founded several healthcare businesses including National Healthcare Analysis Group, Chesapeake Therapeutics and TLC Therapeutics. Robert earned an MBA from Duke University, an MS in Physical Therapy from the University of Indianapolis and a BA from the University of Kansas.
Steven St. Peter, M.D.
Operating Team Member
Steven St. Peter, M.D. is an Operating Team Member at 1315 Capital, a healthcare expansion and growth equity firm. Steven is Managing Director of the JDRF T1D Fund LLC a venture philanthropy focused on curing Type 1 diabetes. From 2012 until 2019, Steven was Founder, President and Chief Executive Officer of Aratana Therapeutics, Inc. (NASDAQ: PETX), an animal health company focused on the licensing, development and commercialization of innovative therapeutics.
Steven was previously a Managing Director at MPM Capital in Boston where his investment scope included both venture and buyout transactions across the pharmaceutical and medical technology industries. His investment experience also includes positions at Apax Partners and The Carlyle Group. Over the past decades, Steven has founded, invested in and/or been involved with several life sciences companies including Align Technologies (NASDAQ: ALGN), Medpointe, ESP Pharma, SkinMedica, Omrix (NASDAQ: OMRI), Pharmathene (NYSE: PIP), Xanodyne, Syndax (NASDAQ: SNDX), EKR Therapeutics, Proteon (NASDAQ: PRTO), Rhythm (NASDAQ:RYTM) and others. Steven has served on the Executive Committee & Board of Directors of the New England Venture Capital Association and he has been active in a variety of other professional organizations.
Previously, Steven was Assistant Clinical Professor of Medicine at Columbia University. He received his M.D. from Washington University and completed his residency and fellowship at the Hospital of the University of Pennsylvania. He also holds an M.B.A. in Finance from the Wharton School of the University of Pennsylvania and a B.A. in Chemistry from the University of Kansas.